Cited 138 time in
- A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein
- C Kim; D K Ryu; J Lee; Y I Kim; J M Seo; Y G Kim; J H Jeong; M Kim; J I Kim; P Kim; J S Bae; E Y Shim; M S Lee; M S Kim; H Noh; G S Park; J S Park; D Son; Y An; J N Lee; Hanseul Oh; Bon-Sang Koo; Jung Joo Hong; Choong-Min Ryu; Y K Choi; S Y Lee
- Bibliographic Citation
- Nature Communications, vol. 12, pp. 288-288
- Publication Year
- Vaccines and therapeutics are urgently needed for the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal antibodies (mAb) targeting the receptor binding domain (RBD) of the viral spike protein via antibody library constructed from peripheral blood mononuclear cells of a convalescent patient. The CT-P59 mAb potently neutralizes SARS-CoV-2 isolates including the D614G variant without antibody-dependent enhancement effect. Complex crystal structure of CT-P59 Fab/RBD shows that CT-P59 blocks interaction regions of RBD for angiotensin converting enzyme 2 (ACE2) receptor with an orientation that is notably different from previously reported RBD-targeting mAbs. Furthermore, therapeutic effects of CT-P59 are evaluated in three animal models (ferret, hamster, and rhesus monkey), demonstrating a substantial reduction in viral titer along with alleviation of clinical symptoms. Therefore, CT-P59 may be a promising therapeutic candidate for COVID-19.
- Springer-Nature Pub Group
- Appears in Collections:
- Ochang Branch Institute > Division of National Bio-Infrastructure > National Primate Research Center > 1. Journal Articles
Division of Research on National Challenges > Infectious Disease Research Center > 1. Journal Articles
- Files in This Item:
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.